Carl L.G. Hansen and Thermopylae Holdings Ltd. filed Amendment No. 4 to a Schedule 13G with the SEC on November 13, 2026, disclosing their beneficial ownership of common shares in AbCellera Biologics Inc. as of September 30, 2026.

Key Highlights

  • Carl L.G. Hansen's total beneficial ownership: 65,913,149 common shares, representing 19.7% of AbCellera Biologics Inc.'s class.
  • Thermopylae Holdings Ltd. ownership: 56,134,097 common shares held directly, representing 17.2% of the class.
  • Share options included: 8,881,052 common shares issuable to Dr. Hansen upon exercise of share options exercisable within 60 days after September 30, 2026, are included in his 19.7% figure.
  • Shares outstanding: 326,332,641 common shares were outstanding as of September 30, 2026, per AbCellera's quarterly report filed November 9, 2026.
  • Thermopylae Holdings Ltd. is wholly owned by Dr. Hansen and is incorporated under the Business Corporations Act of British Columbia, Canada.
  • No shared voting or dispositive power is reported by either reporting person; all power is held solely.

Hansen and Thermopylae Holdings Disclose Ownership Structure in AbCellera Biologics

According to the filing, Carl L.G. Hansen's aggregate beneficial ownership of 65,913,149 common shares in AbCellera Biologics Inc. (NASDAQ:ABCL) is composed of three distinct components. These are 56,134,097 common shares directly owned by Thermopylae Holdings Ltd., which is wholly owned by Dr. Hansen; 898,000 common shares held directly by Dr. Hansen; and 8,881,052 common shares issuable upon exercise of share options exercisable within 60 days after September 30, 2026.

The filing states that the 19.7% ownership percentage attributed to Dr. Hansen is calculated using 326,332,641 common shares outstanding as of September 30, 2026, as disclosed in AbCellera's quarterly report on Form 10-Q filed with the SEC on November 9, 2026, with the exercisable options added to the outstanding share count in accordance with Rule 13d-3(d)(1)(i). AbCellera Biologics, headquartered at 150 W 4th Avenue, Vancouver, British Columbia, is a biotechnology company focused on antibody discovery. Dr. Hansen is a Canadian citizen, and Thermopylae Holdings Ltd. is incorporated under British Columbia law.

Thermopylae Holdings Ltd.'s separate 17.2% figure is based solely on the 326,332,641 outstanding common shares, without the addition of any options, since those options are attributable to Dr. Hansen personally. The filing confirms that neither reporting person holds any shared voting power or shared dispositive power over any portion of the reported shares. This Schedule 13G was filed as Amendment No. 4, indicating prior filings on this same ownership position exist in SEC records.

What Was Disclosed

Amendment No. 4 to a Schedule 13G filed November 13, 2026 discloses that Carl L.G. Hansen and his wholly owned entity Thermopylae Holdings Ltd. beneficially own 65,913,149 and 56,134,097 common shares of AbCellera Biologics Inc., respectively, as of September 30, 2026.